Radiolabeled Glass Beads Used for Treating Patients With Primary Liver Cancer When Surgery is Not an Option

A Humanitarian Device Exemption Use Protocol of TheraSphere for Treatment of Unresectable Hepatocellular Carcinoma

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00740753

Acronym

Y-90HDE

Enrollment

339

Registered

2008-08-25

Start date

2004-08-31

Completion date

2021-04-28

Last updated

2022-09-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatoma, Liver Cancer

Keywords

liver tumor, cancer, hepatoma, yttrium

Brief summary

Fewer than 15% of hepatoma patients are suitable candidates for surgical removal of their cancer. The purpose of this protocol is to provide supervised access at Oregon Health and Science University to Y-90 treatment to provide these patients access to an alternate therapy. The radioactive beads are placed directly near or into the liver tumor with the intention of destroying the tumor cells.

Detailed description

Patients receive Y-90 (yttrium) glass microspheres via percutaneous hepatic arterial infusion. Patients amy be retreated between 30-90 days after initial infusion. After completion of therapy, patients are followed for 30 days and then every 3 months for up to 2 years.

Interventions

DEVICEYttrium 90 (TheraSphere)

Y-90 embedded glass microspheres

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Confirmed diagnosis of HCC * Cancer is unresectable * ECOG Score 0-2 * Age of 18 yrs or over * Able to give consent

Exclusion criteria

* Contraindication to angiography and selective visceral catheterization * Portal hypertension with portal venous shunt away from the liver * Evidence of potential delivery of \> 16.5 mCi of radiation to the lungs * Evidence of any detectable Tc-99m MAA flow to the stomach or duodenum, after application of established angiographic techniques to stop such flow * Significant extrahepatic disease representing an imminent life-threatening outcome * Severe liver dysfunction or pulmonary insufficiency * Active uncontrolled infection * Significant underlying medical or psychiatric illness * Pregnancy

Design outcomes

Primary

Measure	Time frame	Description
Tumor response after treatment based on tumor marker and lab results, CT scan and patient's symptoms.	2 weeks, 1 month and then every 3 months	Tumors will decrease in size

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026